减肥药和给药平台的成长机会

基于 GLP-1 的药物以及注射剂和奈米材料传输平台将推动产业转型

新兴国家可支配收入的增加正在促进世界各地久坐的生活方式。送餐应用程式的出现也增加了人们获取各种美食的机会。这些因素是导致肥胖和其他文明病的主要原因。

身体质量指数 (BMI) 为 30（或 27 kg/m2）或更高的人被归类为肥胖，无论是否有合併症。众所周知，肥胖还会增加多种疾病的风险，包括第 2 型糖尿病、癌症死亡率、全因死亡率和心血管疾病。它还会恶化多种疾病和其他相关合併症的预后。

健康的饮食和积极的生活方式对于维持最佳体重指数非常重要。营养补充，食品膳食纤维、维生素、矿物质和益生菌也有助于控制体重。此外，医疗保健专业人员正在探索肥胖管理的行为介入措施。减重手术是肥胖治疗的黄金标准。然而，最近治疗方法的进展使得口服和注射药物减重成为可能。以 GLP-1 为基础的减肥药正迅速成为肥胖治疗的有力选择，且具有良好的安全性。

在这项研究中，Frost & Sullivan 分析了新核准的减肥药的研发管线以及药物输送技术的相关进展。它还提供了有关资金筹措、减肥药和药物输送平台共同开发的状况、肥胖管理实验状况以及有前途的抗肥胖候选药物的作用机制的见解。

目录

战略问题

• 为什么成长如此困难？策略要务 8 (TM)：阻碍成长的因素
• The Strategic Imperative 8（TM）
• 关键策略要务对肥胖产业的影响
• 成长机会推动Growth Pipeline Engine（TM）
• 调查方法

成长机会分析

• 非传染性疾病 (NCD) 概述
• 范围
• 分割
• 生长促进因子
• 成长抑制因素

肥胖药物管线分析

• 核准的减肥药概述
• 肥胖治疗的游戏规则改变者
• 应对重磅减肥药的挑战
• 肥胖症临床试验形势概述
• 肥胖药物管线分析
• 抗肥胖药物的监管状况：美国和欧洲
• 主要基于 GLP 的双受体促效剂
• 领先的 GLP 为基础的肥胖药物正在进行第 2 期和第 3 期临床试验
• 新型非 GLP减肥药概述

药物输送创新

• 药物输送创新概述
• 给药创新的特点
• 新药物输送创新概况：注射器平台
• 新药物输送创新概览：奈米材料平台

减肥药和交付平台：收购、合作和资金筹措

• 被大型製药企业收购
• 与製药公司的合作
• 肥胖药物输送资金筹措状况概述
• 肥胖药物传递合作伙伴关係概述

肥胖前景

• 肥胖治疗的多方面方法
• 减肥药物输送平台的未来

成长机会宇宙

• 成长机会1：基于GLP-1的多重促效剂
• 成长机会2：个人化治疗策略
• 成长机会3：无针给药技术的利用

下一步

GLP-1-based Drugs, Along With Injector and Nanomaterial Delivery Platforms, Drive Transformational Industry Growth

The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases.

People with a body mass index (BMI) of more than or equal to 30 (or 27kg/m2) are classified as obese and may or may not have co-morbidities. Obesity is also known to increase the risk of several diseases, such as type 2 diabetes, cancer mortality, overall mortality, and cardiovascular disorders. It also worsens the prognosis of several diseases and other related co-morbidities.

An active lifestyle with healthy eating practices is crucial for maintaining optimal BMI. Dietary supplementation with fibers, vitamins, minerals, probiotics, and other nutrients can also help manage weight. In addition, healthcare professionals are exploring behavioral interventions for obesity management. Bariatric surgery is the gold standard for obesity treatment. However, recent therapeutic advancement has enabled the launch of oral and injectable drugs for weight loss. GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.

In this study, Frost & Sullivan analyzes the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies. We also provide insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Obesity Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Overview of Noncommunicable Diseases (NCDs)
• Scope
• Segmentation
• Growth Drivers
• Growth Restraints

Obesity Drugs: Pipeline Analysis

• Overview of Approved Obesity Drugs
• Game Changers for Obesity Management
• Addressing the Challenges of Blockbuster Obesity Drugs
• Overview of the Obesity Clinical Trial Landscape
• Pipeline Analysis of Obesity Drugs
• Regulatory Landscape Overview for Anti-Obesity Drugs: The United States and Europe
• Major Emerging GLP-based Dual Receptor Agonists
• Major Emerging GLP-based Obesity Drugs in Phase 2 and 3 Clinical Trials
• Snapshot of Emerging Non-GLP Obesity Drugs

Drug Delivery Innovations

• Overview of Drug Delivery Innovations
• Features of Drug Delivery Innovations
• Snapshot of Emerging Drug Delivery Innovations: Injector Platforms
• Snapshot of Emerging Drug Delivery Innovations: Nanomaterial Platforms

Obesity Drugs and Delivery Platforms: Acquisitions, Partnerships, and Funding

• Acquisitions by Large Pharma Companies
• Pharma Collaborations
• Overview of the Funding Landscape for Obesity Drug Delivery
• Snapshot of the Partnership Landscape for Obesity Drug Delivery

Obesity Outlook

• A Multipronged Approach to Obesity Management
• The Future of Drug Delivery Platforms for Obesity Management

Growth Opportunity Universe

• Growth Opportunity 1: GLP-1-based Multi-agonists
• Growth Opportunity 2: Individualized Treatment Strategy
• Growth Opportunity 3: The Use of Needle-free Drug Delivery Technologies

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer